field
infecti
diseas
current
crisi
given
increas
preval
infect
highli
resist
microorgan
suscept
exist
antimicrobi
agent
mani
infect
occur
immunosuppress
individu
patient
cancer
organ
transplant
recipi
human
immunodefici
viru
hiv
infect
patient
standard
antimicrobi
therapi
effect
dearth
new
antimicrobi
drug
develop
pipelin
evidenc
pauciti
new
drug
past
decad
last
decad
wit
event
global
outbreak
sever
acut
respiratori
syndrom
introduct
monkeypox
viru
unit
state
emerg
extens
drugresist
tuberculosi
bacteri
infect
environ
need
new
approach
antimicrobi
therapi
specif
need
new
strategi
facilit
rapid
develop
new
antimicrobi
agent
current
strategi
develop
antimicrobi
drug
vaccin
take
mani
year
yield
clinic
use
product
howev
monoclon
antibodi
mab
made
rapidli
linkag
radionuclid
specif
mab
provid
mean
gener
microbicid
antibodi
antibodyantigen
abag
interact
power
tool
circumv
problem
multidrug
resist
radioimmunotherapi
rit
therapeut
modal
use
abag
interact
util
ab
radiolabel
therapeut
radioisotop
select
deliv
lethal
dose
particul
radiat
cell
cancer
treatment
radiolabel
mab
provid
valuabl
altern
cancer
treatment
chemotherapi
extern
radiat
beam
radiat
microbicid
girradi
routin
use
steril
medic
suppli
certain
food
ioniz
radiat
gray
b
especi
aparticl
extern
sourc
kill
differ
strain
bacteria
fungi
escherichia
coli
cryptococcu
neoforman
cn
mycobacterium
tuberculosi
despit
microbicid
properti
radiat
use
current
antimicrobi
therapi
group
propos
use
therapeut
radionuclid
treatment
variou
infect
hypothes
rit
infect
work
sever
waysdin
case
fungal
bacteri
cell
kill
direct
hit
via
crossfir
effect
viral
infect
hiv
goal
rit
would
kill
viru
accomplish
antiretrovir
drug
rather
target
kill
infect
host
cell
viru
propag
call
viral
factori
could
accomplish
target
viral
antigen
express
surfac
infect
host
cell
radiolabel
mab
specif
antigen
final
develop
novel
approach
treatment
infecti
diseas
three
import
factor
taken
consider
new
drug
developmentdefficaci
safeti
mechan
action
cn
serv
first
model
organ
laboratori
develop
infect
rit
cn
encapsul
human
pathogen
fungu
cn
provid
excel
model
chronic
infect
advantag
cn
system
includ
anim
model
includ
pulmonari
mening
latent
infect
avail
verywellcharacter
mab
cn
develop
rit
agent
wellunderstood
pathogenesi
infect
immun
respons
mab
cn
capsular
polysaccharid
antigen
use
clinic
trial
patient
cryptococc
mening
first
seri
experi
efficaci
rit
cn
infect
test
ajcr
mice
nci
nih
mous
strain
select
suscept
cn
infect
presum
partial
complement
defici
mice
partial
complement
defici
succumb
rapidli
dissemin
infect
infect
iv
nine
group
ajcr
femal
mice
infect
iv
cn
cell
mice
treat
differ
dose
mab
control
mab
unlabel
mab
phosphatebuff
salin
mice
treat
radiolabel
mab
live
significantli
longer
averag
mice
given
radiolabel
phosphatebuff
salin
use
irrelev
immunoglobulin
mab
control
possibl
fc
receptor
bind
radiolabel
phagocyt
site
infect
might
result
nonspecif
kill
remark
day
therapi
mice
bigroup
aliv
treatment
mci
p
group
anim
aliv
treatment
p
mci
p
respect
surviv
mice
dose
depend
rang
mci
bi
significantli
mice
surviv
mcidos
group
dose
mci
although
effici
elimin
fungal
load
target
organ
shown
colonyform
unit
cfu
prove
radiotox
shown
toxic
studi
optim
treatment
dose
mice
appear
mci
rang
mice
infect
cn
given
rit
significantli
reduc
fungal
burden
lung
brain
hour
treatment
infect
mice
control
group
although
differ
reduct
fungal
burden
lung
group
receiv
mci
treatment
mci
significantli
lower
lung
cfu
rel
lower
activ
p
henc
administr
cnspecif
radiolabel
mab
prolong
surviv
reduc
organ
fungal
burden
infect
mice
low
level
cfu
detect
lung
surviv
anim
sacrif
complet
surviv
studi
followup
experi
compar
rit
amphotericin
b
current
standard
care
treatment
invas
fungal
infect
remark
singl
inject
bilabel
complet
elimin
cn
infect
lung
brain
mice
wherea
cours
amphotericin
b
unabl
significantli
lower
fungal
burden
organ
current
develop
rit
treatment
blastomyc
dermatitidi
fungal
pathogen
affect
companion
dog
human
immunocompromis
also
healthi
individu
experi
evalu
safeti
rit
healthi
dog
current
ongo
follow
clinic
trial
rit
companion
dog
blastomycosi
success
result
provid
crucial
data
efficaci
safeti
rit
larg
anim
requir
fda
health
canada
human
translat
bacillu
anthraci
power
agent
use
biolog
warfar
infect
organ
associ
high
rate
mortal
underscor
need
addit
effect
therapi
anthrax
investig
rit
approach
could
success
use
toxinbind
mab
diseas
caus
toxigen
bacteria
indirect
immunofluoresc
studi
mab
protect
antigen
lethal
factor
reveal
surfac
express
toxin
bacteri
cell
scatchard
analysi
mab
reveal
high
bind
constant
numer
bind
site
bacteri
surfac
evalu
microbicid
properti
mab
group
radiolabel
mab
bi
vitro
bi
effici
mediat
microbicid
activ
b
anthraci
b
anthraci
releas
tripartit
toxin
compos
cellbind
protein
known
protect
antigen
two
enzym
compon
call
edema
factor
lethal
factor
administr
bilabel
mab
protect
antigen
lethal
factor
prolong
surviv
ajcr
mice
infect
b
anthraci
stern
bacteri
cell
result
indic
rit
mab
target
b
anthraci
toxin
compon
use
treat
experiment
anthrax
infect
suggest
toxigen
bacteria
may
target
radiolabel
mab
total
joint
replac
last
resort
treatment
degen
joint
diseas
fear
complic
prosthet
joint
infect
pji
incid
primari
hip
arthroplasti
primari
knee
arthroplasti
pji
difficult
treat
bacteria
form
biofilm
prosthet
materi
hinder
host
immun
system
importantli
bacteria
biofilm
mostli
dormant
state
therefor
suscept
antibiot
current
collabor
dr
van
der
wal
weinan
van
dijk
univers
medic
center
utrecht
netherland
investig
whether
alpharit
direct
toward
wall
teichoic
acid
staphylococcu
aureu
major
pathogen
caus
pji
kill
methicillinresist
aureu
thu
provid
proof
principl
data
need
develop
rit
strategi
noninvas
treatment
pji
hivaid
remain
enorm
public
health
burden
advanc
combin
antiretrovir
therapi
greatli
reduc
mortal
morbid
hiv
remain
incur
peopl
live
hiv
suffer
numer
comorbid
treatmentrel
side
effect
even
strict
art
adher
significantli
increas
risk
cognit
deficit
cancer
osteoporosi
etc
earlier
age
uninfect
popul
art
act
block
hiv
replic
step
thu
prevent
infect
new
cell
kill
exist
infect
cell
longliv
cell
popul
rest
memori
cell
cell
monocyt
lineag
act
reservoir
harbor
infecti
hiv
even
peopl
live
hiv
undetect
peripher
viru
level
reservoir
form
within
first
month
hiv
infect
interrupt
art
reestablish
product
infect
addit
cellular
reservoir
anatom
reservoir
creat
celltocel
spread
inabl
drug
reach
therapeut
concentr
variou
tissu
central
nervou
system
cn
particularli
vulner
hiv
neuroinvas
occur
earli
day
peripher
infect
bloodbrain
barrier
bbb
restrict
passag
mani
art
drug
result
sustain
viral
replic
increas
likelihood
emerg
drugresist
strain
infect
system
site
addit
even
presenc
nonrepl
viru
contribut
reinfect
peripheri
cn
reactiv
neurocognit
disord
affect
patient
hiv
unit
state
preval
increas
longer
life
span
hivinfect
individu
earli
aggress
treatment
art
substanti
reduc
size
total
reservoir
stabl
popul
latent
infect
cell
appear
unaffect
earli
art
peripheri
cn
remain
reservoir
hiv
even
success
art
fact
recent
data
indic
even
art
regimen
penetr
cn
decreas
hivassoci
neurocognit
disord
often
make
wors
far
unsuccess
attempt
cure
hiv
use
bone
marrow
transplant
new
treatment
elimin
anatom
cellular
reservoir
hiv
need
report
use
rit
radiolabel
mab
effect
target
hivinfect
cell
proofofprincipl
experi
use
rit
erad
hiv
infect
util
human
mab
glycoprotein
lead
candid
rit
compon
conjug
alphaemitt
bi
human
mab
glycoprotein
safe
elimin
hivinfect
human
peripher
blood
mononuclear
cell
implant
sever
combin
immunodefici
mice
hematolog
toxic
base
platelet
count
rit
specif
kill
hivinfect
cell
peopl
two
differ
art
regimen
individu
use
radiolabel
mab
demonstr
nonactiv
latent
infect
cell
monocyt
lymphocyt
lineag
express
low
level
surfac
nevertheless
suffici
target
kill
rit
radiolabel
mab
abl
penetr
extent
vitro
human
bbb
select
kill
infect
monocyt
peripher
blood
mononuclear
cell
transmigr
across
barrier
resid
cn
mab
use
home
devic
rit
nonneutr
put
select
pressur
infecti
agent
although
rit
caus
transient
longterm
myelodysplasia
neutropenia
thrombocytopenia
patient
cancer
overal
safeti
record
rit
strong
particularli
import
light
continu
high
mortal
low
success
rate
bone
marrow
transplant
gene
therapi
approach
treat
hiv
current
develop
novel
human
antibodi
better
penetr
intact
bbb
subsequ
test
first
stateoftheart
human
hiv
mous
model
tripleknockout
mice
engraft
fetal
human
bone
marrow
liver
thymu
tkoblt
mice
follow
studi
simianhuman
immunodefici
virusinfect
nonhuman
primat
rit
develop
treatment
cancer
decad
ago
experiment
result
repeatedli
provid
strong
evid
potenti
use
rit
differ
microbi
infect
fact
microb
express
antigen
uniqu
differ
host
antigen
simplic
target
high
specif
low
crossreact
may
potenti
achiev
fewer
complic
recent
approv
sever
target
radionuclid
therapi
cancer
arena
europ
unit
state
demonstr
medic
commun
becom
much
will
util
therapi
patient
care
believ
combin
immun
radiat
therapi
provid
excit
new
strategi
may
potenti
use
varieti
intract
infecti
diseas
